📇 Rhumatologue · ST PIERRE · (974) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Centre hospitalier universitaire (CHU) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
27 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
119.7 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
CHU SITE SUD (SAINT PIERRE)
AV FRANCOIS MITTERRAND BP 350 TERRE SAINTE, 97410 ST PIERRE
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
The Lancet. Respiratory medicine · 2021
European respiratory review : an official journal of the European Respiratory Society · 2019
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung disease, characterised by progressive scarring of the lung and associated with a high burden of disease and early death. The pathophysiological understanding, clinical diagnostics and therapy of IPF have significantly evolved in recent years. While the recent introduction of the two antifibrotic drugs pirfenidone and nintedanib led to a significant reduction in lung function decline, there is still no cure for IPF; thus, new therapeutic approaches are needed. Currently, several clinical phase I–III trials are focusing on novel therapeutic targets. Furthermore, new approaches in nonpharmacological treatments in palliative care, pulmonary rehabilitation, lung transplantation, management of comorbidities and acute exacerbations aim to improve symptom control and quality of life. Here we summarise new therapeutic attempts and potential future approaches to treat this devastating disease.
Chest · 2010
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Science translational medicine · 2026 · Journal Article
Merkt W, Rodon L, Deicher FS, Freitag M, et al.
Frontiers in medicine · 2023 · Journal Article
Buschulte K, Höger P, Ganter C, Wijsenbeek M, et al.
Respiratory research · 2022 · Journal Article
Wilkens FM, Ganter C, Kriegsmann K, Wilkens H, et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022 · Journal Article
Röhrich M, Leitz D, Glatting FM, Wefers AK, et al.
Presse medicale (Paris, France : 1983) · 2020 · Journal Article
Torrisi SE, Kahn N, Vancheri C, Kreuter M
BMC pulmonary medicine · 2019 · Journal Article
Torrisi SE, Kahn N, Wälscher J, Sarmand N, et al.
Journal of thoracic disease · 2018 · News
Kahn N, Vanfleteren LEGW, Kaltsakas G, Andrianopoulos V, et al.
Journal of thoracic disease · 2017 · Journal Article
Kahn N, Andrianopoulos V, Mekov E, Herth FJF
American journal of respiratory and critical care medicine · 2015 · Journal Article
Fritzsching B, Zhou-Suckow Z, Trojanek JB, Schubert SC, et al.
Chest · 2010 · Journal Article
Herth FJ, Krasnik M, Kahn N, Eberhardt R, et al.
Respiration; international review of thoracic diseases · 2026 · Journal Article
Habibie H, Putri KSS, Boorsma CE, Brass DM, et al.
Respiration; international review of thoracic diseases · 2023 · Journal Article
Buschulte K, Höger P, Ganter C, Wijsenbeek M, et al.
Respiration; international review of thoracic diseases · 2020 · Journal Article
Tzilas V, Kahn N, Bouros D
Cancers · 2018 · Journal Article
Schneider MA, Muley T, Weber R, Wessels S, et al.
Respiration; international review of thoracic diseases · 2018 · Journal Article
Kahn N, Rossler AK, Hornemann K, Muley T, et al.
Oncotarget · 2016 · Journal Article
Schneider MA, Muley T, Kahn NC, Warth A, et al.
Frontiers in pharmacology · 2021 · Journal Article
Torrisi SE, Kahn N, Wälscher J, Polke M, et al.
The European respiratory journal · 2020 · Journal Article
Behr J, Prasse A, Wirtz H, Koschel D, et al.
The Lancet. Respiratory medicine · 2021 · Journal Article
Behr J, Prasse A, Kreuter M, Johow J, et al.
Respiration; international review of thoracic diseases · 2020 · Comparative Study
Koczulla AR, Boeselt T, Koelpin J, Kaufhold F, et al.
Health and quality of life outcomes · 2020 · Journal Article
Maqhuzu PN, Szentes BL, Kreuter M, Bahmer T, et al.
Respiratory research · 2019 · Journal Article
Kreuter M, Swigris J, Pittrow D, Geier S, et al.
Frontiers in pharmacology · 2021 · Journal Article
Torrisi SE, Kahn N, Wälscher J, Polke M, et al.
Single-cell RNA-Seq of human primary lung and bronchial epithelium cells
This dataset contains count matrices and per-cells metadata tables for RNA sequencing of 39778 single nuclei from healthy primary lung samples of 12 lung adenocarcinoma patients as well as 17451 single human bronchiole e
Cost drivers in the pharmacological treatment of interstitial lung disease
Abstract Introduction Treatments of interstitial lung diseases (ILDs) mainly focus on disease stabilization and relief of symptoms by managing inflammation or suppressing fibrosis by (in part costly) drugs. To highlight
The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry
Abstract Background Quality of life (QoL) is profoundly impaired in patients with idiopathic pulmonary fibrosis (IPF). However, data is limited regarding the course of QoL. We therefore analysed longitudinal data from th
Single-cell RNA-Seq of human primary lung and bronchial epithelium cells
This dataset contains count matrices and per-cells metadata tables for RNA sequencing of 39778 single nuclei from healthy primary lung samples of 12 lung adenocarcinoma patients as well as 17451 single human bronchiole e
Is YouTube a sufficient source of information on Sarcoidosis?
Abstract Background The internet is a common source of health information for patients and caregivers. To date, content and information quality of YouTube videos on sarcoidosis has not been studied. The aim of our study
YouTube-videos for patient education in lymphangioleiomyomatosis?
Abstract Background The Internet is commonly used by patients to acquire health information. To date, no studies have evaluated the quality of information available on YouTube regarding lymphangioleiomyomatosis (LAM). Ou
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Respiration; international review of thoracic diseases · 2020 · Comparative Study
Koczulla AR, Boeselt T, Koelpin J, Kaufhold F, et al.
Respiration; international review of thoracic diseases · 2020 · Comparative Study
Polke M, Kirsten D, Teucher B, Kahn N, et al.
European respiratory review : an official journal of the European Respiratory Society · 2019 · Journal Article
Somogyi V, Chaudhuri N, Torrisi SE, Kahn N, et al.
Respiration; international review of thoracic diseases · 2018 · Journal Article
Kahn N, Rossler AK, Hornemann K, Muley T, et al.
Respiration; international review of thoracic diseases · 2014 · Journal Article
Oltmanns U, Kahn N, Palmowski K, Träger A, et al.
Respiration; international review of thoracic diseases · 2010 · Journal Article
Eberhardt R, Kahn N, Herth FJ
Clinical proteomics · 2015 · Journal Article
Kahn N, Riedlinger J, Roeßler M, Rabe C, et al.
Respiratory research · 2019 · Journal Article
Kreuter M, Swigris J, Pittrow D, Geier S, et al.